In a recent report, Bernstein provided an optimistic outlook for the US SMID-Cap Biotech sector in 2024. This positive stance ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE